PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership
Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission
Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base
Conference call and webcast to be held today, March 30, at 8:30 AM EST
NEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. $(PAVM)$ ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025.
Conference Call and Webcast
The webcast will take place on Monday, March 30, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
Business Update Highlights
"Over the past two years, we've undertaken a series of deliberate, systematic actions to fix PAVmed's legacy capital structure and strengthen its balance sheet," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "This process is now complete and we believe PAVmed is exceptionally well positioned to execute on its founding mission -- to operate as a high-growth diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model. Veris is now well underway in the commercial phase of its strategic engagement with OSU-The James while progressing its implantable physiological monitor toward FDA submission. Lucid continues to maintain a strong commercial foundation as it approaches transformative Medicare coverage for EsoGuard. We have also relaunched PAVmed's medical device portfolio under experienced leadership and completed the licensing of our endoscopic esophageal imaging technology from Duke University, adding another potential growth engine to our pipeline."
Highlights from the fourth quarter and recent weeks:
-- PAVmed strengthened its balance sheet through the completion of a $30
million Series D preferred stock offering and a $15 million senior
secured note financing. A portion of the proceeds from these activities
was used to eliminate all previously outstanding convertible securities,
removing a significant legacy capital structure overhang and extending
the Company's cash runway. In addition, the Company issued $30 million in
Series D warrants, which are callable upon the publication of a draft CMS
coverage policy for Lucid's EsoGuard Esophageal DNA Test.
-- PAVmed relaunched its medical device portfolio and appointed industry
veteran Joseph Virgilio as Chief Business Officer of Medical Devices to
oversee development and commercialization of its current and future
device portfolio, including the PortIO implantable intraosseous vascular
access device and endoscopic esophageal imaging technology licensed from
Duke University.
-- Veris advanced its strategic engagement with The Ohio State University's
James Cancer Hospital, with the commercial phase well underway and full
integration with the hospital's electronic health record (EHR) system now
complete.
-- Veris is engaged with its development and manufacturing partner for its
implantable physiological monitor, supporting a planned late 2026 FDA
510(k) submission.
-- Lucid Diagnostics announced fourth quarter and full year 2025 financial
results and key business developments, including:
-- Recognized $1.5 million in EsoGuard$(R)$ Esophageal DNA Test revenue
for 4Q25 and processed 3,664 EsoGuard tests.
-- Awarded U.S. Department of Veterans Affairs (VA) contract for
EsoGuard, expanding access across the nation's largest integrated
healthcare system serving approximately nine million veterans.
-- Announced positive data from the largest reported real-world
experience of esophageal precancer detection, evaluating Lucid's
EsoGuard and EsoCheck(R) Esophageal Cell Collection Device in
nearly 12,000 at-risk patients.
Financial Results:
-- For the three months ended December 31, 2025, Operating expenses were
approximately $6.9 million which include stock-based compensation
expenses of $0.3 million. GAAP net loss attributable to common
stockholders was approximately $1.8 million, or $(2.05) per common share
on a diluted basis.
-- As shown below and for the purpose of illustrating the effect of
stock-based compensation and other non-cash income and expenses on the
Company's financial results, the Company's non-GAAP adjusted loss was
approximately $0.9 million or $(1.05) per common share.
-- PAVmed had cash and cash equivalents of $1.5 million as of December 31,
2025, compared to $1.2 million as of December 31, 2024.
-- The audited financial results for the year ended December 31, 2025 were
filed with the SEC on Form 10-K on March 27, 2026, and are available
at www.pavmed.com or www.sec.gov.
PAVmed Non-GAAP Measures
-- To supplement our financial results presented in accordance with U.S.
generally accepted accounting principles (GAAP), management provides
certain non-GAAP financial measures of the Company's financial results.
These non-GAAP financial measures include net loss before interest, taxes,
depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which
further adjusts EBITDA for stock-based compensation expense, loss on the
issuance or modification of convertible securities, the periodic change
in fair value of convertible securities, and loss on debt extinguishment.
The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted
loss are not recognized terms under U.S. GAAP.
-- Non-GAAP financial measures are presented with the intent of providing
greater transparency to the information used by us in our financial
performance analysis and operational decision-making. We believe these
non-GAAP financial measures provide meaningful information to assist
investors, shareholders, and other readers of our financial statements in
making comparisons to our historical financial results and analyzing the
underlying performance of our results of operations. These non-GAAP
financial measures are not intended to be, and should not be, a
substitute for, considered superior to, considered separately from, or as
an alternative to, the most directly comparable GAAP financial measures.
-- Non-GAAP financial measures are provided to enhance readers' overall
understanding of our current financial results and to provide further
information for comparative purposes. Management believes the non-GAAP
financial measures provide useful information to management and investors
by isolating certain expenses, gains, and losses that may not be
indicative of our core operating results and business outlook.
Specifically, the non-GAAP financial measures include non-GAAP adjusted
loss, and its presentation is intended to help the reader understand the
effect of the loss on the issuance or modification of convertible
securities, the periodic change in fair value of convertible securities,
the loss on debt extinguishment and the corresponding accounting for
non-cash charges on financial performance. In addition, management
believes non-GAAP financial measures enhance the comparability of results
against prior periods.
-- A reconciliation to the most directly comparable GAAP measure of all
non-GAAP financial measures included in this press release for the three
months and year ended December 31, 2025 and 2024 are as follows:
Condensed Consolidated Statement of Operations (Unaudited)
For the three months ended For the year ended
December 31, December 31,
2025 2024 2025 2024
---------------- -------------- --------------- ---------------
(in thousands
except per-share
amounts)
Revenue $ 52 $ 10 $ 71 $ 2,995
Operating expenses 6,853 5 198 21,877 47,482
Other (Income)
Expense (4,046) (6 330) (19,337) (72,914)
---------------- -------------- --------------- ---------------
Net (Income) Loss 2,755 (1,142) 2,469 (28,427)
---------------- -------------- --------------- ---------------
Net income (loss)
per common share,
diluted $ (2.05) $ 3.60 $ (5.63) $ 14.90
Net income (loss)
attributable to
common
stockholders (1,832) 1,346 (3,774) 31,966
Preferred Stock
dividends and
deemed dividends 569 85 4,175 7,825
(MORE TO FOLLOW) Dow Jones Newswires
March 30, 2026 08:00 ET (12:00 GMT)
Comments